• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹腔镜肝切除术治疗伴有临床显著门脉高压症的肝细胞癌的安全性和可行性:一项倾向评分匹配研究。

Safety and feasibility of laparoscopic liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a propensity score-matched study.

机构信息

Department of General Surgery, School of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, 3 East Qingchun Road, Hangzhou, 310016, Zhejiang, China.

出版信息

Surg Endosc. 2021 Jul;35(7):3267-3278. doi: 10.1007/s00464-020-07763-6. Epub 2020 Jul 6.

DOI:10.1007/s00464-020-07763-6
PMID:32632488
Abstract

BACKGROUND

The presence of clinically significant portal hypertension (CSPH) remains a relative contraindication to liver resection for patients with resectable hepatocellular carcinoma (HCC). The goal of this study was to explore whether a laparoscopic approach could extend the indications for hepatectomy to patients with PH.

METHOD

Patients who underwent laparoscopic liver resection (LLR) from February 2016 to September 2019 performed by a single medical team were included in this study. We analyzed the surgical and oncological outcomes between groups with and without CSPH before and after propensity score matching (PSM).

RESULT

We enrolled 156 patients divided into two groups according to the presence (CSPH, n = 26) or absence (non-CSPH, n = 130) of CSPH. CSPH group was associated with more clinical signs of liver dysfunction (p < 0.05). After PSM (n = 48 patients), the CSPH group tended to have a longer postoperative hospital stay (p = 0.054); however, there was no difference in operation time (p = 0.329), blood loss volume (p = 0.392), transfusion rates (p = 0.701), rate of conversion to open surgery (p = 0.666), surgical margin (p = 0.306), surgical mortality (n = 0), or comprehensive complication index (p = 0.844) between the two groups. The median follow-up time for the entire cohort was 19.6 months (range 0.2-40.6 months). The 3-year overall survival rate was 62.9% in the CSPH group and 84.3% in the non-CSPH group (p = 0.1090), and results were similar after PSM (p = 0.5734).

CONCLUSIONS

LLR is safe and feasible for HCC with PH. The introduction of minimally invasive surgery, represented by LLR, can appropriately expand the indications for hepatectomy.

摘要

背景

对于可切除肝细胞癌(HCC)患者,存在临床显著门静脉高压症(CSPH)仍然是肝切除术的相对禁忌症。本研究的目的是探讨腹腔镜方法是否可以将肝切除术的适应证扩展到 PH 患者。

方法

本研究纳入了 2016 年 2 月至 2019 年 9 月期间由同一医疗团队进行腹腔镜肝切除术(LLR)的患者。我们分析了 CSPH 组(n=26)和非 CSPH 组(n=130)患者在倾向评分匹配(PSM)前后的手术和肿瘤学结果。

结果

我们根据是否存在 CSPH(CSPH 组,n=26)将 156 例患者分为两组,将其分为 CSPH 组和非 CSPH 组。CSPH 组的肝功能不全临床征象更为明显(p<0.05)。PSM 后(n=48 例),CSPH 组的术后住院时间较长(p=0.054);但手术时间(p=0.329)、失血量(p=0.392)、输血率(p=0.701)、中转开腹率(p=0.666)、切缘(p=0.306)、手术死亡率(n=0)和综合并发症指数(p=0.844)无差异。整个队列的中位随访时间为 19.6 个月(范围 0.2-40.6 个月)。CSPH 组的 3 年总生存率为 62.9%,非 CSPH 组为 84.3%(p=0.1090),PSM 后结果相似(p=0.5734)。

结论

对于 PH 的 HCC,LLR 是安全可行的。以 LLR 为代表的微创外科的引入,可以适当扩大肝切除术的适应证。

相似文献

1
Safety and feasibility of laparoscopic liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a propensity score-matched study.腹腔镜肝切除术治疗伴有临床显著门脉高压症的肝细胞癌的安全性和可行性:一项倾向评分匹配研究。
Surg Endosc. 2021 Jul;35(7):3267-3278. doi: 10.1007/s00464-020-07763-6. Epub 2020 Jul 6.
2
Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study.腹腔镜肝切除术治疗肝细胞癌合并门静脉高压症的疗效:一项病例匹配研究。
Surg Endosc. 2018 May;32(5):2345-2354. doi: 10.1007/s00464-017-5930-1. Epub 2017 Dec 7.
3
Laparoscopic and open minor liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a multicenter study using inverse probability weighting approach.腹腔镜和开腹小肝癌切除术治疗伴有临床显著门静脉高压的肝细胞癌:一项使用逆概率加权法的多中心研究。
Surg Endosc. 2024 Feb;38(2):757-768. doi: 10.1007/s00464-023-10591-z. Epub 2023 Dec 5.
4
Safety of laparoscopic hepatectomy in patients with hepatocellular carcinoma and portal hypertension: interim analysis of an open prospective study.腹腔镜肝切除术治疗肝细胞癌合并门静脉高压症患者的安全性:一项开放前瞻性研究的中期分析。
Surg Endosc. 2019 Mar;33(3):811-820. doi: 10.1007/s00464-018-6347-1. Epub 2018 Jul 12.
5
Prognosis and safety of laparoscopic hepatectomy for BCLC stage 0/A hepatocellular carcinoma with clinically significant portal hypertension: a multicenter, propensity score-matched study.腹腔镜肝切除术治疗伴有临床显著门脉高压的 BCLC 分期 0/A 期肝细胞癌的预后和安全性:一项多中心、倾向评分匹配研究。
Surg Endosc. 2024 Feb;38(2):799-812. doi: 10.1007/s00464-023-10589-7. Epub 2023 Dec 7.
6
Laparoscopic liver resection for hepatocellular carcinoma complicated with significant portal hypertension: A propensity score-matched survival analysis.腹腔镜肝切除术治疗合并重度门静脉高压的肝细胞癌:倾向评分匹配生存分析
Hepatobiliary Pancreat Dis Int. 2023 Aug;22(4):358-365. doi: 10.1016/j.hbpd.2022.03.012. Epub 2022 Mar 22.
7
Laparoscopic Liver Resection for Hepatocellular Carcinoma in Child-Pugh A Patients With and Without Portal Hypertension: A Multicentre Study.腹腔镜肝切除术治疗 Child-Pugh A 级合并与不合并门静脉高压的肝细胞癌:一项多中心研究。
World J Surg. 2020 Nov;44(11):3915-3922. doi: 10.1007/s00268-020-05687-9. Epub 2020 Jul 13.
8
Microwave ablation versus laparoscopic resection for hepatocellular carcinoma in patients with clinically significant portal hypertension: a propensity score-matched study of postoperative liver decompensation.微波消融与腹腔镜肝切除术治疗伴有临床显著门脉高压的肝细胞癌:术后肝功能失代偿的倾向性评分匹配研究。
Eur Radiol. 2024 May;34(5):3226-3235. doi: 10.1007/s00330-023-10268-0. Epub 2023 Oct 25.
9
Laparoscopic hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: a systematic review and meta-analysis.腹腔镜肝切除术治疗伴有临床显著门脉高压的肝细胞癌:系统评价和荟萃分析。
World J Surg Oncol. 2024 Jan 3;22(1):3. doi: 10.1186/s12957-023-03264-7.
10
Laparoscopic versus open limited liver resection for hepatocellular carcinoma with liver cirrhosis: a propensity score matching study with the Hiroshima Surgical study group of Clinical Oncology (HiSCO).腹腔镜与开腹局限性肝切除术治疗肝硬化肝细胞癌的比较:来自广岛临床肿瘤外科学会(HiSCO)的倾向评分匹配研究。
Surg Endosc. 2020 Nov;34(11):5055-5061. doi: 10.1007/s00464-019-07302-y. Epub 2019 Dec 11.

引用本文的文献

1
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus-related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinical trial.部分肝切除术与介入治疗对乙型肝炎病毒相关肝细胞癌合并临床显著门静脉高压患者的随机对照临床试验。
Cancer Commun (Lond). 2024 Nov;44(11):1337-1349. doi: 10.1002/cac2.12614. Epub 2024 Sep 25.
2
Laparoscopic hepatectomy for hepatocellular carcinoma in patients with clinically significant portal hypertension: a systematic review and meta-analysis.腹腔镜肝切除术治疗伴有临床显著门脉高压的肝细胞癌:系统评价和荟萃分析。
World J Surg Oncol. 2024 Jan 3;22(1):3. doi: 10.1186/s12957-023-03264-7.
3

本文引用的文献

1
A novel simple intra-corporeal Pringle maneuver for laparoscopic hemihepatectomy: how we do it.一种用于腹腔镜半肝切除术的新型简单的腔内阻断法:我们的操作方法。
Surg Endosc. 2020 Jun;34(6):2807-2813. doi: 10.1007/s00464-020-07513-8. Epub 2020 Mar 23.
2
A novel model for predicting posthepatectomy liver failure in patients with hepatocellular carcinoma.一种用于预测肝细胞癌患者肝切除术后肝功能衰竭的新模型。
PLoS One. 2019 Jul 3;14(7):e0219219. doi: 10.1371/journal.pone.0219219. eCollection 2019.
3
Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis.
A systematic review and meta-analysis of blood transfusion rates during liver resection by country.
按国家对肝切除术中输血率进行的系统评价和荟萃分析。
Ann Surg Treat Res. 2023 Dec;105(6):404-416. doi: 10.4174/astr.2023.105.6.404. Epub 2023 Nov 29.
4
Prognosis and safety of laparoscopic hepatectomy for BCLC stage 0/A hepatocellular carcinoma with clinically significant portal hypertension: a multicenter, propensity score-matched study.腹腔镜肝切除术治疗伴有临床显著门脉高压的 BCLC 分期 0/A 期肝细胞癌的预后和安全性:一项多中心、倾向评分匹配研究。
Surg Endosc. 2024 Feb;38(2):799-812. doi: 10.1007/s00464-023-10589-7. Epub 2023 Dec 7.
5
Laparoscopic and open minor liver resection for hepatocellular carcinoma with clinically significant portal hypertension: a multicenter study using inverse probability weighting approach.腹腔镜和开腹小肝癌切除术治疗伴有临床显著门静脉高压的肝细胞癌:一项使用逆概率加权法的多中心研究。
Surg Endosc. 2024 Feb;38(2):757-768. doi: 10.1007/s00464-023-10591-z. Epub 2023 Dec 5.
6
Microwave ablation versus laparoscopic resection for hepatocellular carcinoma in patients with clinically significant portal hypertension: a propensity score-matched study of postoperative liver decompensation.微波消融与腹腔镜肝切除术治疗伴有临床显著门脉高压的肝细胞癌:术后肝功能失代偿的倾向性评分匹配研究。
Eur Radiol. 2024 May;34(5):3226-3235. doi: 10.1007/s00330-023-10268-0. Epub 2023 Oct 25.
7
Minimally invasive liver surgery for hepatocellular carcinoma in patients with portal hypertension.门静脉高压症患者肝细胞癌的微创肝脏手术
BJS Open. 2023 Mar 7;7(2). doi: 10.1093/bjsopen/zrad037.
8
Challenging Scenarios and Debated Indications for Laparoscopic Liver Resections for Hepatocellular Carcinoma.肝细胞癌腹腔镜肝切除术的挑战性场景及存在争议的适应证
Cancers (Basel). 2023 Feb 27;15(5):1493. doi: 10.3390/cancers15051493.
9
Current status of radical laparoscopy for treating hepatocellular carcinoma with portal hypertension.根治性腹腔镜手术治疗门静脉高压性肝细胞癌的现状
World J Clin Cases. 2021 Apr 16;9(11):2419-2432. doi: 10.12998/wjcc.v9.i11.2419.
肝细胞癌治疗策略的比较疗效:系统评价与网状Meta分析
BMJ Open. 2018 Oct 18;8(10):e021269. doi: 10.1136/bmjopen-2017-021269.
4
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
5
Safety of laparoscopic hepatectomy in patients with hepatocellular carcinoma and portal hypertension: interim analysis of an open prospective study.腹腔镜肝切除术治疗肝细胞癌合并门静脉高压症患者的安全性:一项开放前瞻性研究的中期分析。
Surg Endosc. 2019 Mar;33(3):811-820. doi: 10.1007/s00464-018-6347-1. Epub 2018 Jul 12.
6
Open Liver Resection, Laparoscopic Liver Resection, and Percutaneous Thermal Ablation for Patients with Solitary Small Hepatocellular Carcinoma (≤30 mm): Review of the Literature and Proposal for a Therapeutic Strategy.孤立性小肝癌(≤30mm)患者的肝切除术、腹腔镜肝切除术及经皮热消融术:文献综述及治疗策略建议
Dig Surg. 2018;35(4):359-371. doi: 10.1159/000489836. Epub 2018 Jun 11.
7
Does Intermittent Pringle Maneuver Increase Postoperative Complications After Hepatectomy for Hepatocellular Carcinoma? A Randomized Controlled Trial.间歇性Pringle手法会增加肝细胞癌肝切除术后的并发症吗?一项随机对照试验。
World J Surg. 2018 Oct;42(10):3302-3311. doi: 10.1007/s00268-018-4637-3.
8
Benefits of laparoscopic liver resection in patients with hepatocellular carcinoma and portal hypertension: a case-matched study.腹腔镜肝切除术治疗肝细胞癌合并门静脉高压症的疗效:一项病例匹配研究。
Surg Endosc. 2018 May;32(5):2345-2354. doi: 10.1007/s00464-017-5930-1. Epub 2017 Dec 7.
9
Laparoscopic liver resections for hepatocellular carcinoma. Can we extend the surgical indication in cirrhotic patients?腹腔镜肝切除术治疗肝细胞癌。我们能否扩大肝硬化患者的手术适应证?
Surg Endosc. 2018 Feb;32(2):617-626. doi: 10.1007/s00464-017-5711-x. Epub 2017 Jul 17.
10
The Comprehensive Complication Index (CCI®): Added Value and Clinical Perspectives 3 Years "Down the Line".综合并发症指数(CCI®):3 年后的附加价值和临床视角。
Ann Surg. 2017 Jun;265(6):1045-1050. doi: 10.1097/SLA.0000000000002132.